<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616664</url>
  </required_header>
  <id_info>
    <org_study_id>2019_45</org_study_id>
    <secondary_id>2020-A01991-38</secondary_id>
    <nct_id>NCT04616664</nct_id>
  </id_info>
  <brief_title>Diagnostic Accuracy of the &quot;LLIFT&quot;, a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome&quot;</brief_title>
  <acronym>LLIFT</acronym>
  <official_title>Diagnostic Accuracy of the &quot;LLIFT&quot;, a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RHU PreciNASH Task 1.4</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Région Nord-Pas de Calais, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NAFLD is the first cause of liver disease worldwide. The severe form of NAFLD, the NASH&#xD;
      progresses to cirrhosis and is responsible of liver mortality. The diagnosis of NASH requires&#xD;
      liver biopsy that cannot be used for the screening of the disease.&#xD;
&#xD;
      The broad prevalence of the disease limits also the generalization of liver biopsy even for&#xD;
      diagnosis. There is an urgent need for the use and the validation of liver diagnosis&#xD;
      biomarkers for the diagnosis of NASH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The Area under receiver operating characteristic (ROC) curve (AUC) of the LLIFT (Lille LIver Fat Test)-NASH score</measure>
    <time_frame>Baseline</time_frame>
    <description>The variables constituting the calculation algorithm are : clinical data (age, gender, BMI, diabetes status), biological data (AST, ALT, GCT, fasting glucose, HbA1c, triglyceride,...) and genetic polymorphism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Area under receiver operating characteristic (ROC) curve (AUC) of the LLIFT (Lille LIver Fat Test)- steatosis score</measure>
    <time_frame>Baseline</time_frame>
    <description>The variables constituting the algorithm are : clinical data (age, gender, BMI, diabetes status), biological data (AST, ALT, GCT, fasting glucose, HbA1c, triglyceride,..), genetic polymorphism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the correlation between the LLIFT score and the NAS score</measure>
    <time_frame>Baseline</time_frame>
    <description>The NAS score is a stratification based on steatosis, ballooning and lobular inflammation.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1027</enrollment>
  <condition>Obesity</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients are followed in the cardiology, endocrinology, hepatology, hepatologic surgery and&#xD;
        bariatric surgery units of the CHU de Lille and regional centers and presente type 2&#xD;
        diabetes or blood pressure hypertension associated with increased hepatic enzyme.&#xD;
&#xD;
        Patients will be referred to the hepatology units and included in the study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with 1 at least of the following metabolic criteria :&#xD;
&#xD;
               -  BMI &gt; 30 kg/m²,&#xD;
&#xD;
               -  Type 2 diabetes (glycemia &gt; 1.26 g/L or under therapy)&#xD;
&#xD;
               -  hypertension (&gt; 140 mmHg / 90 mmHg or under therapy) associated with increased&#xD;
                  hepatic enzymes&#xD;
&#xD;
          -  Indication of NAFLD evaluation&#xD;
&#xD;
          -  Patients written consent&#xD;
&#xD;
          -  Affiliated to a social insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for liver biopsy or MRI.&#xD;
&#xD;
          -  Other confounding cause of liver disease (HCV, HBV, HCC, autoimmune liver disease,&#xD;
             Hemochromatosis, Wilson disease.&#xD;
&#xD;
          -  alcohol consumption higher than 140g/week for women and 210g/week for men&#xD;
&#xD;
          -  Previous history of alcohol abuse (addiction).&#xD;
&#xD;
          -  Eluding stent &lt; 6 month or acute coronary syndrome within 1 year or non-eluding stent&#xD;
             within 6 weeks.&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Being processed Cancer (chemotherapy, radiotherapy or hormone therapy)&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Drug abuse within the past year.&#xD;
&#xD;
          -  Mentally unbalanced patients, under supervision or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Lassailly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Lassailly, MD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>guillaume.lassailly@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH ARRAS</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH LENS</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hop Claude Huriez Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GHIRCL saint Philibert</name>
      <address>
        <city>Lomme</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ch Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NAFL</keyword>
  <keyword>NASH screening</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>Diagnostic Biomarker</keyword>
  <keyword>non-invasive biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

